André Pelegrin

Title: The Innovative Mind of André Pelegrin: Advancements in Cancer Treatment

Introduction

André Pelegrin, a prominent inventor based in Montpellier, France, has made significant contributions to the field of medical research and cancer treatment. With a total of six patents to his name, Pelegrin's work focuses on developing novel antibodies that target specific receptors involved in cancer progression. His groundbreaking inventions are paving the way for new therapeutic approaches that hold great promise for patients.

Latest Patents

One of André Pelegrin's latest patents is for anti-human-HER3 antibodies and their uses. This invention details a neuregulin non-competitive allosteric anti-human-HER3 antibody characterized by a human constant region. Remarkably, this antibody possesses less than 65% of the glycan structures carrying fucose molecules at its glycosylation site, and it is distinguished by specific variable sequences.

Another significant patent is focused on a combination therapy using anti-EGFR and anti-HER2 antibodies. This innovative approach aims to enhance cancer treatment effectiveness, particularly for cancers expressing high levels of EGFR and low levels of HER2. The patent describes the combined usage of the monoclonal antibody 'trastuzumab' (HERCEPTIN®) targeting HER2 receptors and the monoclonal antibody 'matuzumab' (hmAB 425, EMD 72000) directed at EGF receptors. The result is a combination treatment specifically aimed at patients with cancer, notably pancreatic cancer, who have this receptor profile.

Career Highlights

André Pelegrin has had an illustrious career, working at prestigious institutions such as the Institut National de la Santé et de la Recherche Médicale (INSERM) and the University of Montpellier. His dedication to medical research and innovation has led him to focus on critical areas that promise to transform cancer treatment paradigms.

Collaborations

Throughout his career, Pelegrin has collaborated with notable colleagues, including Isabelle Teulon and Christel Larbouret. These partnerships have fostered an environment conducive to cutting-edge research and the development of life-saving medical interventions.

Conclusion

André Pelegrin stands out as a key figure in the field of medical innovation, particularly in cancer treatment through targeted therapies. His contributions significantly advance our understanding and approach to treating various cancers, highlighting the potential of innovative antibodies and combination therapies. With a commitment to research and collaboration, Pelegrin continues to make strides that may soon change the landscape of cancer treatment.